We previously demonstrated that the orphan nuclear receptor, estrogen receptor-related receptor a (ERRa) is highly expressed in osteoblasts and osteoclasts, regulates osteogenesis and expression of osteoblast-associated markers in the rat calvaria cell differentiation system, and is dysregulated in the rat ovariectomy model of postmenopausal osteoporosis. There are conflicting published data on the transcriptional regulation by ERRa of the gene for osteopontin (OPN), an extracellular matrix protein required in bone remodeling, and a potential direct target mediating ERRa effects in bone. We therefore readdressed OPN gene regulation by ERRa in both osteoblastic (rat osteosarcoma ROS17/2.8 cells) and non-osteoblastic (HeLa) cell lines using a mouse proximal 2 kb OPN promoter fragment. A minimal OPN promoter fragment spanning from K56 to C9 bp is activated in HeLa cells but repressed it in ROS17/2.8 cells. Adenine scanning mutagenesis revealed the presence of a non-canonical ERRa response element in this minimal promoter. Surprisingly, prototypical inactivating mutations in the activation function 2 (AF2) domain or a naturally occurring allelic variant of ERRa (ERRaH408) were all better activators than wild-type ERRa in HeLa cells, activities that were generally paralleled by repression in ROS17/2.8 cells. Finally, we found that the N-terminus of ERRa harbors a repressor domain that acts in a cell context-dependent manner. We conclude that OPN is an ERRa target gene whose promoter is regulated by ERRa in a cell context-dependent manner and that a predicted silencing mutation in AF2 or a more flexible helix 12 increases ERRa transcriptional activity, effects with implications for ERRa as a therapeutic target in bone.
Introduction
Nuclear receptors (NRs) are structurally and functionally modular with the N-terminal A/B domain regulating transcriptional activity in a ligand-independent fashion (activation function 1 (AF1)) and a conserved centrally located DNA-binding domain (DBD) composed of two zinc fingers. The DBD allows the NR to control transcription directly by binding to cognate response elements found in a subset of promoters or indirectly by tethering to other transcription factors (Kushner et al. 2000 , Safe et al. 2004 ). The C-terminal ligand/hormone-binding domain (HBD) is composed of 12 a-helices that form a centrally located ligand-binding pocket, with helix 12 harboring the ligand-dependent AF2 (Bourguet et al. 2000) . NRs are controlled by a large and increasing number of co-repressors and co-activators, the balance of which determines transcriptional activity (Privalsky 2004 , Spiegelman & Heinrich 2004 . Generally, co-repressors bind to a hydrophobic surface in the HBD and are released due to a conformational shift involving helices 3, 5, and 12 upon ligand binding, which repositions the AF2 domain, closing the ligand-binding pocket to form a new hydrophobic binding surface allowing co-activators to bind (Nettles & Greene 2005) . The binding of the co-activator to the NR is greatly stabilized by a charge clamp involving a conserved lysine (K) in helix 3 and either a glutamic acid (E) or aspartic acid (D) found in the AF2 domain (Li et al. 2003) . Recent evidence has pointed to an important role for the A/B domain in binding the co-activators and interactions with the C-terminus of the NR (Schaufele et al. 2005) .
The estrogen receptor-related receptor (ERR) subfamily of NRs comprises three distinct genes (ERRa (nuclear receptor 3b;NR3B1), ERRb (NR3B2), and ERRg (NR3b3)) most closely related to the estrogen receptor (ER) subfamily (ERa (NR3A1) and ERb (NR3A2)) with 68% identity in their DBD (Nuclear Receptors Nomenclature Committee 1999 , Giguere 2002 . ERRs bind to a response element (ERRE) with the consensus sequence 5 0 -TCAAGGTCA-3 0 , while the ER response element (ERE) comprises two inverted repeats of 5 0 -AGGTCA-3 0 separated by three nucleotides (Giguere 2002) . The similarity in their respective response elements and the high conservation of their DBD underlie the ability of ERR and ER to regulate some genes via either response element (Giguere 2002 , Bonnelye & Aubin 2005 . The solved crystal structure of the ERRa HBD showed that it is too small to accommodate estrogen or similar ligands (Kallen et al. 2004) , explaining why ERRa does not bind and is not activated by estrogen directly. However, estrogen binding to ERa upregulates ERRa expression (Shigeta et al. 1997 and ERa can physically interact with ERRa (Yang et al. 1996) , strengthening the idea that these two receptor families impinge on each others signaling (Vanacker et al. 1999a , Kraus et al. 2002 . Intriguingly, the crystal structure of ERRa also suggests that the AF2 domain is in the traditional activated conformation, supporting the view that ERRa acts as a constitutive weak activator (Kallen et al. 2004) . It must be recognized, however, that the crystal structure was solved for ERRa bound with the co-activator peroxisome proliferator activated receptor gamma co-activator 1 alpha (PGC1a), suggesting that helix 12 may not always be in the active conformation. In any case, while maximal activation by ERRa requires co-activators, including PGC1a (Huss et al. 2002 , Schreiber et al. 2003 , Gaillard et al. 2007 , less is known about ERR and co-repressor interactions, although ERRa is known to interact with the co-repressors DSS-AHC critical region on the X chromosome, gene 1 (DAX1), small heterodimer partner (SHP), and receptor interacting protein (RIP140) (Sanyal et al. 2002 , Park et al. 2005 , Castet et al. 2006 . We reported previously that ERRa expression is much higher than that of ERa or ERb in bone and cartilage and that upregulation of ERRa increases, while antisense knockdown reduces, bone and cartilage formation in cell culture models (Bonnelye et al. 2001 (Bonnelye et al. , 2007 . Concomitantly, we observed regulation of a number of genes necessary for, and/or associated with, the differentiation programs in both osteoblast and chondrocyte lineages (Aubin 2001 , Lefebvre & Smits 2005 . Among those regulated in osteoblasts were osteopontin (OPN; Bonnelye et al. 2001) , a secreted phosphorylated multifunctional glycoprotein whose regulation depends on a number of NRs with roles in bone biology (Noda et al. 1990 , Craig & Denhardt 1991 , Vanacker et al. 1998 , Lee et al. 2000 , Bonnelye et al. 2001 , Denhardt et al. 2001 , Ogawa et al. 2005 , Shen & Christakos 2005 . However, there are conflicting reports on the regulation of OPN by ERRa in osteoblastic cells, with some reporting upregulation (Vanacker et al. 1998 , Bonnelye et al. 2001 and others reporting downregulation, the latter via interference of ERRa with the orphan NR nuclear receptor related 1 (Nurr1) (Lammi et al. 2004) . We therefore readdressed OPN regulation by ERRa and report that mOPN regulation by ERRa is cell context dependent and does not involve the previously identified ERRE, but rather a non-canonical site overlapping the inverted CAAT box. We also provide evidence that mutation or complete removal of the AF2 domain renders mERRa a more potent activator dependent on the presence of the A/B domain. Our data suggest that interactions between the N-and C-termini influence the alignment of the AF2 domain and subtle changes in this interaction dictate the transcriptional response and presumably the interactions with co-regulatory molecules.
Materials and methods

Plasmids
The ERRa open reading frame was amplified using RT-PCR from mouse muscle cDNA and cloned into a modified pcDNA3.1 vector (Invitrogen) that had the SV40 promoter replaced with an internal ribosome entry site to make pcDINmERRa. Point mutations and deletions of mERRa were made using standard PCR approaches with pcDINmERRa as the starting plasmid and oligonucleotides that incorporated restriction sites for cloning and mutation identification (Ausubel et al. 1987) . The OPN promoter plasmids pGL2mOPN-1981C78 and pGL2mOPN-624C78 were a kind gift from D A Towler (Bidder et al. 2002) . Additional OPN promoter deletions and mutations were made using standard techniques and cloned into pGL2B (Promega). The mammalian Gal4 DNA-binding domain expression vectors pM1-3 and pM1VP16 were a kind gift from Sadowski & Ptashne (1989) and the pFRluc reporter plasmid was obtained from Stratagene (La Jolla, CA, USA). The pM1 plasmid was modified to allow construction of both N-and C-terminal Gal4 fusion proteins. The pGFP-C1 plasmid was from Clontech. The pSilencer 3.1-H1 hygro and pSilencer negative control (pSi neg) plasmids were obtained from Ambion, Inc. The oligonucleotide 5 0 -GATC-CAGGGTTCCTCAGAGACTGATTCAAGAGATCAGT-CTCTGAGGAACCCTTTTTTTGGAAA-3 0 targeting the 5 0 -end of mouse and rat ERRa was designed with the program at the Ambion web site (www.ambion.com) and cloned into pSilencer 3.1 to make pSi 5 0 a. Other oligonucleotide sequences used in making the plasmids are available upon request. All plasmids were sequence verified.
Cell culture
All cells were kept in a humidified incubator at 37 8C in a 95% air-5% CO 2 atmosphere. HeLa cells (gift from L Attisano, University of Toronto) were maintained in Dulbecco's modified Eagle's medium (DMEM) (D5796, Sigma) C10% fetal bovine serum (FBS), MC3T3-E1 clone 26 cells (Wang et al. 1999) were maintained in aMEM C10% FBS, and ROS17/2.8 cells (Majeska et al. 1985) were maintained in aMEM C15% FBS. Cells were routinely passaged at 80-90% confluence and were plated onto 24-well plates at the cell density described in the figure legends the day before transfection. On the day of transfection, the medium was changed and cells were transfected using Lipofectamine 2000 (Invitrogen) with 10 ng pRLtkluc (Promega) as internal control for transfection efficiency. Luciferase activities were measured 48 h later on an EG&G Berthold Microplate Luminometer LB96V (EG&G Berthold GMBH & Co., Bad Wildbad, Germany) using the Dual-Luciferase reporter assay system (Promega). Transfections were repeated at least thrice and a representative experiment is shown. To confirm that changes in endogenous ERRa expression level altered OPN gene expression, ROS 17/2.8 cells at 70% confluence in 6-well plates were transiently transfected using Lipofectamine 2000 with 5 mg of either pSi neg or pSi 5 0 a, and RNA was extracted 48 h later using TRI reagent (Sigma) following the manufacturer's instructions. After conversion of the RNA to cDNA with Superscript II (Invitrogen), realtime PCR was performed (Bio-Rad MyiQ cycler) and relative expression levels of rOPN were determined using rL32 as internal control.
Electrophoretic mobility shift assay (EMSA) EMSA was performed essentially as described (Ausubel et al. 1987) . Briefly, either the wild-type mOPN promoter oligonucleotides 5 0 -TCGAGCAGCTGATTGGTGGA-GACTGTCTGGACCAGCATTT-3 0 and 5 0 -AAATGCT GGTCCAGACAGTCTCCACCAATCAGCTGC-3 0 or the mutant 6A2 oligonucleotides 5 0 -TCGAGCCATGGCTGATTaaaaaaGACTGTCTGGACCAGCATTT-3 0 and 5 0 -AAATGCTGGTCCAGACAGTCttttttAATCAGCCATG-GC-3 0 were annealed and the resulting overhang was filled in with [a-32 P]dCTP and Klenow fragment. The probe was purified using a spun column and 30 000 c.p.m. of probe were used in the binding reaction. HeLa cells were transfected with either control vector (pcDIN), full length ERRa (pcDINmERRa), or ERRa DNA-binding mutant (pcDINmERRaC99G) and nuclear extracts were prepared 48 h after transfection. The probe and nuclear extracts were combined and incubated on ice for 20 min before being loaded on a pre-run 0 . 5% TrisBorate-Ethylenediaminetetraacetic acid (TBE) nondenaturing gel at 4 8C for 2 h, dried, and exposed to film. For competition experiments, either 10-or 50-fold excess unlabeled oligonucleotide was included in the incubation step.
Statistical analysis
All data are plotted as meansGS.D. of triplicate determinations; results of representative experiments are shown and experiments were repeated a minimum of thrice. Data were analyzed using Student's t-test.
Results
ERRa does not regulate mOPN via the S1 element in osteoblasts or HeLa cells
We made sequential deletions of a 2 kb fragment of the mOPN promoter so as to progressively delete previously identified putative ERREs S1-S6 (Vanacker et al. 1998; Fig. 1A) . Based on basal activity of the 2 kb or truncated promoter constructs in HeLa cells, we identified a positive regulatory element between K789 and K629 and a negative regulatory element between K629 and K419 (Fig. 1B) . Deletion to K24 resulted in a further dramatic decrease, consistent with removal of the CAAT and TATA boxes that have been shown to be required for basal promoter activity (Kabe et al. 2005 , Hummelshoj et al. 2006 . Co-transfection of the mOPN promoter constructs with mERRa caused a two-to threefold enhancement over basal promoter activity in HeLa cells until sequences between K253 and K24 were deleted (Fig. 1B) . Transfection of the same constructs into the osteoblastic ROS 17/2 . 8 cell line showed similar trends in basal promoter activity (compare Fig. 1B and C) ; however, co-transfection of the promoter constructs with mERRa repressed (30-50%) promoter activity until sequences between K253 and K24 were deleted (Fig. 1C) . Real-time PCR analysis of ROS17/2.8 cells overexpressing ERRa (data not shown) or underexpressing ERRa (shRNA-transfected cells) confirmed that ERRa represses OPN in ROS17/2.8 cells (Fig. 1D) . We conclude that mERRa regulates the mOPN promoter in a cell contextdependent manner independently of the previously identified ERREs (S1 element) and that the regulatory element lies between K253 and K24. mERRa regulates the mOPN promoter through a non-canonical ERRE A transcription element search system (TESS) database (Schug 2003) search of the proximal K253 to C78 bps of the mOPN promoter for transcription factor binding sites revealed an abundance of predicted specificity protein 1 (SP1) as well as two AP1 sites. The upstream AP1 site is thought to be used by a variety of signaling pathways (Bidder et al. 2002 , Ogawa et al. 2005 ) and the downstream AP1 site overlaps the CAAT box. Visual inspection of the sequence identified a weak consensus ERRE (GGGAGGTCT) between K17 and K9 which also overlaps a predicted SP1 site. To determine whether mERRa utilized any of these predicted sites, we made a series of promoter deletions and mutated the newly predicted ERRE1 from GGGAGGTCT to GGGgaaTCT (m1), which would abolish ERR binding and destroy the SP1 site ( Fig. 2A) . Deletion of sequences between C10 and C78 had no effect on basal promoter activity in HeLa cells nor did it diminish the ability of mERRa to activate the K253 to C9 mOPN promoter (Fig. 2B) . Mutation of the putative ERRE1 slightly increased the basal promoter activity, but did not abolish the ability of mERRa to activate the K253 to C9 m1 construct (Fig. 2B) . Since mERRa was shown previously to act through SP1 sites (Castet et al. 2006) that are still present in the K253 to C9 construct, we tested a minimal mOPN promoter from K56 to C9 that retains the CAAT and TATA boxes, as well as a previously identified binding site for Smad proteins (Hullinger et al. 2001 ; Fig. 2D ). Removal of the upstream SP1 sites reduced activity of the K56 to C9 basal promoter while mutating the ERRE1/SP1 site in K56 to C9 m1 had no further effect (Fig. 2B) . Importantly, mERRa still activated or repressed these two minimal promoters in HeLa or ROS17/2.8 cells respectively, indicating that the regulation was not due to the predicted ERRE1 or SP1 sites in either case.
To further delineate the site used by mERRa to regulate mOPN, we made adenine scanning mutations (Fig. 2D) . The wild-type K56 to C9 promoter and adenine scan mutants 6A3 and 6A4 gave robust activation in the presence of mERRa (Fig. 2E) , whereas 6A1 and 6A2 had minimal effects on basal promoter activity while completely abolishing the ability of mERRa to activate the mOPN promoter in HeLa cells (Fig. 2E) . In ROS17/2.8 cells, on the other hand, 6A1 and more so 6A2 abolished mERRa's ability to repress the promoter while the wild-type or the 6A3 and 6A4 promoter mutant constructs still repressed (Fig. 2F) . Notably, basal promoter activity is much more affected by the 6A1 and 6A2 mutations in ROS17/2.8 cells than in HeLa cells (compare Fig. 2E and F) . These results suggest that regulation of mOPN is through a non-canonical binding site or through interaction with proteins bound near the CAAT box but not the Smad site. (Liu et al. 1996 , Jakacka et al. 2001 . A DBD mutant, mERRaC99G, increased promoter activity (30%) over basal levels in HeLa cells (Fig. 3A) , indicating that on the 2 kb mOPN promoter, mERRa activates transcription by both DBD-dependent and DBD-independent modes. However, an intact DBD was required for activating the K629 and smaller mOPN promoter deletions (Fig. 3A) . In ROS17/2.8 cells, repression was observed for both the wild-type and the DBD mutant mERRa (Fig. 3B ), indicating that repression in the osteoblastic cells most likely involves protein-protein interactions; this interaction appears to be mediated by protein(s) that binds between the CAAT box and the Smad site as repression is no longer observed in the 6A2 promoter mutant (Fig. 3B) . Repression is observed in the 6A3 promoter mutant indicating that mERRa does not require binding to Smads to repress in ROS17/2.8 cells.
In an EMSA using a K56 to K24 probe, we detected four complexes (I to IV), all of which were competed away with unlabeled oligonucleotide (Fig. 3C, compare  lanes 2 and 4) . Transfecting HeLa cells with control vector diminished complex IV (Fig. 3C , compare lanes 5 and 6), however, we should point out that complex IV showed variable intensity between different nuclear protein extracts (data not shown). Transfection of mERRa reduced the intensity of complexes I and II (Fig. 3C, lanes 6 and 7) , while mERRaC99G did not (Fig. 3C, lanes 6 and 8) indicating potential ERRa binding to complexes I and II. Incubation of the 6A2 mutant oligonucleotide with any of the HeLa cell extracts caused loss of complexes I and II only (Fig. 3C , compare lanes 5-8 with 9-12), while use of the 6A2 mutant oligonucleotide as competitor of labeled wt probe caused loss of III and IV only (data not shown).
Role of the AF2 domain of ERRa in transcriptional regulation of mOPN
The AF2 domain is required for maximal transcriptional activation by most NRs (Bourguet et al. 2000) . However, deletion of amino acids 413-419 of mERRa to create mERRamAF2 (Fig. 4A) , which lacks helix 12 including the important E415 that forms part of the charge clamp and should render mERRa transcriptionally inactive, surprisingly led to greater activation of the 2 kb mOPN promoter than seen with wt mERRa (Fig. 4B, compare wt with mAF2 ). This novel observation suggested that either E415 is less important in co-activator binding or that the smaller C-terminus allowed for better binding of co-activators. Most ERRa isoforms reported have a proline at position 408 (P408) preceding helix 12, but the originally described mERRa (Giguere et al. 1988 ) has a histidine (H) at this position (Fig. 4A) . When we tested the H408 allele (mERRaH408) on the 2 kb mOPN promoter in HeLa cells, we found that it is more active than the wt mERRa allele (Fig. 4B) , supporting the notion that conformational flexibility in helix12 affects the transcriptional outcome. Similarly to what we observed with mERRamAF2, an AF2 domain deletion of the H408 allele (mERRaH408mAF2) is also an even better activator of the 2 kb promoter than mERRaH408 (Fig. 4B , compare H408 and H408mAF2). The mERRaH408 was also more active than mERRa on all of the promoter deletions that we tested in HeLa cells (data not shown). We tested the same series of mERRa constructs with the K253 to C9 mOPN promoter and observed the same trends as with the 2 kb mOPN promoter (Fig. 4B) . The mERRamAF2 deletion places the terminal aspartic acid (D422) residue in the same relative position as would be occupied by E415 (Fig. 4A) , potentially leaving the charge clamp intact which could explain why mERRamAF2 is more active. If this were the case, then a C-terminal deletion to E515 should mimic the result we obtained with mERRamAF2, but the mERRaDC415 mutant was totally inactive on the K253 to C9 mOPN promoter (Fig. 4C , compare DC415 with mAF2) and the K629C78 and the K56C9 promoters (data not shown). A mutant with the charge reversed, mERRaDCE415N, as well as a deletion mutant to amino acid 414 (mERRaDC414), mimicked mERRamAF2 activity (Fig. 4C and data not shown) indicating that the charge clamp residue in the AF2 domain is dispensible for activation. A larger C-terminal deletion that removes both helices 11 and 12 (mERRaDC392) retained the ability to activate mOPN (Fig. 4C) , and the degree of activation depended on the amount of mOPN promoter that was present in the luciferase constructs, but was always less than that seen with mERRamAF2 (data not shown). When we mutated the other charge clamp residue (K243) to alanine (mERRaK243A), both the K629C78 and the K56C9 mOPN promoters were activated two-to threefold (data not shown), while the K253C9 promoter was unresponsive (Fig. 4C) . Taken together, these data suggest that one charge clamp residue is sufficient to recruit co-activators to mERRa depending on the promoter context, while the positioning of helix 12 determines the strength of the transcriptional response. 
The A/B and HBD domains of mERRa have opposing transcriptional activities
To determine whether the different domains of mERRa behave independently, we next tested several Gal4DBD fusion proteins (Fig. 5A ) using a luciferase reporter containing 5! Gal4 binding sites in both HeLa (Fig. 5B ) and ROS17/2 . 8 (Fig. 5C ) cells. Fusing Gal4DBD (Gal4) to the N-terminus of full length mERRa or the previously hyperactive mERRamAF2 or mERRaDC392 mutants repressed the Gal4 reporter in HeLa cells (Fig. 5B) . This, together with the fact that the wt HBD fused to Gal4 activated the reporter fourfold while the mAF2HBD and DC3292HBD were incapable of activating the reporter (Fig. 5B) , supports the notion that the N-terminus plays a role in controlling the activity of mERRa. Similar trends were seen in ROS17/2.8 cells where, intriguingly, the wt HBD elicited a very robust 28-fold activation compared with the Gal4 control alone while the mAF2HBD and DC392HBD fusions were inactive (Fig. 5C ), suggesting that the N-terminus acts as a repressor of mERRa activity. We tested this further by fusing the A/B domain of mERRa to either the N-terminus of Gal4, which preserves the relative domain orientation in the native protein, or the C-terminus of Gal4. Irrespective of how the A/B domain was fused or the cell line used, the Gal4 reporter luciferase was repressed ( Fig. 5B and C) , indicating that the A/B domain of mERRa harbors a repressor function and that there is communication between the A/B and AF2 domains in native mERRa.
To further address the hypothesis that fusing protein domains to the N-terminus affects the ability of mERRa to regulate the mOPN promoter by disrupting N-/Cterminal communication, we fused GFP (244 amino acids), Gal4 (148 amino acids), or VP16 (48 amino acids) to the N-terminus of mERRa and tested them on the 2 kb, K253 and K56 mOPN promoters. Consistent with our previous results, native mERRa activated all three of the mOPN promoters two-to threefold in HeLa cells, the GFP and the VP16 fusions abolished activation of all three promoters, and the Gal4 fusion activated both the K253 and K56 mOPN reporters but not the 2 kb promoter (Fig. 5D) . In ROS17/2.8 cells, mERRa represses all three mOPN reporters (Fig. 5E ) as we had demonstrated before (Fig. 1C) . GFPmERRa repressed only the K253 mOPN promoter, while GAL4mERRa repression was indistinguishable from that of the native mERRa on all three of the reporters (Fig. 5E ). VP16mERRa activated the 2 kb mOPN promoter about twofold (Fig. 5E ) and activated the endogenous rOPN promoter as shown by real-time PCR (data not shown) indicating that VP16 can turn mERRa into a constitutive activator. However, VP16mERRa repressed the K253 and K56 promoters (Fig. 5E ). The data indicate that proper conformation of the N-terminus and promoter context are important in regulating the transcriptional activity of mERRa.
Discussion
We report here that mERRa is a cell context-dependent regulator of the mOPN promoter through a noncanonical binding site, activating in HeLa cells but repressing in the osteoblastic ROS17/2.8 cells. We also found that the AF2 domain was dispensable for this activation while the A/B domain functions as a repressor, a repressor function that can be masked by the carboxy terminus of mERRa in a cell contextdependent manner.
mERRa and cell context-dependent regulation of the mOPN promoter Previous studies were discrepant in showing either that mERRa positively regulates mOPN mediated by two ERRE sites (S1 and S2) around 700 bps upstream from the transcription start site in HEK293 and ROS17/2.8 cells (Vanacker et al. 1998) or that it has no effect on its own but blocks Nurr1-mediated transactivation of OPN in the osteoblastic SaOS cell line (Lammi et al. 2004) . These latter authors demonstrated that Nurr1 bound to the S1 site in a manner not competable by ERRa, suggesting that ERRa acted through a different site (Lammi et al. 2004) . Our data support the view that mOPN repression by mERRa in the osteoblastic cell lines is mediated through a novel site. The basis of the discrepancy in activation versus repression in ROS17/2.8 cells is at present unclear. However, a serum factor that modulates mERRa activity (Vanacker et al. 1999b ) seems an unlikely explanation, given that three different batches of serum gave us comparable results (data not shown). Sequence polymorphisms in the mOPN promoters may contribute to the differences in regulation observed, as they are known to do in human OPN (Giacopelli et al. 2004 , Hummelshoj et al. 2006 . We also cannot discount the possibility that the ROS17/2.8 cells have diverged between laboratories (Grigoriadis et al. 1985) and are expressing different subsets/levels of co-activators or co-repressors; such a possibility is supported by the ability of PGC1a to turn mERRa into an activator when it is cotransfected into unresponsive HeLa cells . In any case, our observation that endogenous OPN expression was repressed in ERRa-transfected ROS17/2.8 cells and increased in ROS17/2.8 cells transfected with shRNA against ERRa (Fig. 1D) is consistent with ERRa being a negative regulator of OPN transcription in the osteoblastic cells, a result we confirmed in the mouse preosteoblast cell line MC3T3-E1 (clone26; data not shown). It is also worth noting that neither we (NIH 3T3 fibroblasts; data not shown) nor others (NB-E fibroblasts; Vanacker et al. 1998) have been able to detect either repression or activation of the OPN promoter in fibroblastic cells; we also have not detected regulation of OPN by ERRa in the monkey kidney (Cercopithecus aethiops 1 (COS1)) or rat chondrocyte (C5 . 18) cell lines (data not shown).
Requirement for an intact DBD is cell context dependent Activation of mOPN in HeLa cells depends on a noncanonical site at K56 to K45 and requires a functional DBD, as disruption of the second zinc finger in the mERRaC99G construct abolished activation. The residual activity observed with the K2 kb mOPN promoter construct suggests that in this context mERRaC99G is tethered to other transcription factors. Although we demonstrated that mERRa alters the binding of protein complexes at this site in a DBDdependent manner, we were not able to show definitive direct binding of mERRa to this site by EMSA, nor were we able to supershift the complexes using a commercially available antibody (data not shown). This suggests that mERRa binds to the site only weakly/transiently or via protein-protein interactions. It is known that the K56 to K45 region is important for basal transcriptional activity and is capable of binding the CAAT box factor NF-Y (Kabe et al. 2005) , but whether mERRa binds to the K56 to K45 region directly or uses NF-Y as a bridging factor is at present not known. Nevertheless, it is notable that repression of mOPN by mERRa in ROS17/2.8 cells is mediated by the same non-canonical ERRE element, but does not require an intact DBD, suggesting that mERRa binds to different factors or adopts a different conformation when interacting with the promoter in ROS17/2 . 8 versus HeLa cells.
mERRa domain requirements and interactions in the regulation of the mOPN promoter Our data suggest the novel conclusion that helix 12 of mERRa is not only dispensible for activation, but also its absence renders mERRa hyperactive. In most NRs, helix 12 contributes several residues that form part of the hydrophobic surface and the charge clamp, the latter formed by two conserved amino acids, a lysine (K) residue in helix 3 (K243 in mERRa) and in most NRs a glutamic acid (E) in helix 12 (E415 in mERRa). A few NRs have an aspartic acid (D) in helix 12 as part of their charge clamp. Co-activators bind to the AF2 domain via a LXXLL motif (L is leucine and X is any amino acid) termed the NR interaction domain, with amino acids surrounding this core sequence imparting NR selectivity and binding affinity (Gaillard et al. 2006) . Our mERRamAF2 mutant deletes amino acids 413-419, removing all of helix 12, including the charge clamp E415 and several hydrophobic residues that form part of the co-activator binding surface (Kallen et al. 2004) . The fact that this made mERRa hyperactive not only in HeLa cells but also in other cell lines and with other promoters (data not shown), suggests that mERRamAF2 is either able to recruit co-activators better or bind them in a different conformation such that a more active complex results. In support of this idea is the observation that reducing the hydrophobicity by mutating leucines to alanines in helix 12 of ERRa has been shown to reduce but not abolish activity, suggesting that such a mutated ERRa still binds co-activators (Kraus et al. 2002 , Zhang et al. 2006 , including PGC1a or RIP140 (Huss et al. 2002 , Castet et al. 2006 . Neutralizing the charge in helix 12 has also been shown to activate ERRa depending on the promoter/co-activator used (Gaillard et al. 2007) . Our data with mERRamAF2, which carries a change predicted to keep the charge clamp intact, suggest that charge per se is less important than having one less carbon in the side chain as demonstrated by the mERRaDCE415N mutant. The charge near the C-terminus is totally dispensible as a deletion mutant to residue 392 (mERRaDC392) activates transcription of the mOPN promoter with an activity between that of wild-type and mERRamAF2 levels depending on the promoter complexity. Mutation of the other charge clamp residue K243 to alanine retains activity, which varied with the size of the promoter fragment used. Taken together, the data suggest that in ERRa only one of the charge clamp residues is sufficient to allow binding of co-activator(s). This is consistent with recent data from Gaillard et al. (2007) who demonstrated that in order to abolish ERRa activation of a 3! ERE-TATA-luc reporter by PGC1a, both the charge clamp residues had to be neutralized. The fact that activation via another co-activator, SRC2, was abolished by neutralizing the charge clamp in either helix 3 (K243A) or AF2 domain (triple mutant K411N, E415Q, E418Q) suggests that these interactions are co-activator, and most likely, promoter context dependent.
We also found that more subtle changes in the conformation of helix 12, i.e., H408 versus P408, increase the activity of mERRa. We predict that the H408 compared with the P408 allele imparts more degrees of rotational freedom to helix 12, perhaps better accommodating co-activator binding or conversely reducing co-repressor binding. There is precedent to suggest that subtle changes in the conformation of the AF2 domain alter co-activator binding (Paige et al. 1999 , Nettles & Greene 2005 . Such allelic changes could have important biological and clinical consequences for carriers. For example, increased ERRa expression, due to an autoregulatory ERRa promoter polymorphism comprising amplification of ERRE elements, is correlated with higher bone mineral density (BMD) and body mass index (BMI) in certain populations (Kamei et al. 2005 , Laflamme et al. 2005 . Our results suggest that the H408 allele, which also exists in the rat (Accession # NP_001008511), may also influence BMD and BMI by being more active.
A second novel conclusion, based on our results with heterologous protein domains fused to mERRa, is that the N-terminus of mERRa contains a repressor domain whose activity is influenced by cell and promoter context and it is the interplay between the N-and C-termini that affect the transcriptional outcome. We uncovered a repressor domain within the A/B domain of mERRa (Fig. 5 and (Zhang & Teng 2001) ) that, somewhat surprisingly, can shut down the strong activation activity of VP16 (Sladek et al. 1997 ). This was not due to a defective VP16 fusion protein since we detected an appropriately sized protein by western blotting and the VP16mERRa activates transcription of a 3! ERRE-tk-luc plasmid (data not shown). Further support for a regulatory interaction between the N-and C-termini of ERRa comes from our HBD mutants, and the data again suggest that repression is dominant over the ability to activate. This is not because a repressor is bound to the HBD, as the wt HBD fused to the Gal4 DBD gave a robust 28-fold activation, suggesting that ROS17/2.8 cells are not lacking an activator molecule, but rather that the N-terminal part of mERRa is able to suppress the activation. Proximity of the N-and C-termini for NRs has been described and, in the case of the androgen receptor (AR), it plays an important role in activating transcription: the N-terminus of AR contains a sequence FXXLF that binds to its own AF2 domain with the net result being longer ligand retention (He et al. 1999) . The N-and C-termini of AR have also been shown to interact in a yeast two hybrid test and FRET (He et al. 1999 , Schaufele et al. 2005 . The A/B domain of mERRa is quite short and does not posses a sequence resembling either FXXLF or LXXLL, however, that does not preclude the possibility that the N-and C-termini are in close spatial proximity. In other NRs, it has also been demonstrated that while co-activator(s) bind to the AF2 domain with its LXXLL motif, other parts of the co-activator(s) bind sequences in the N-terminus. Our data are consistent with a model in which at least two out of the three regions (A/B, K243, or AF2) of mERRa cooperate to regulate transcription. Thus, the structure of the N-terminus of mERRa appears to be more important than previously appreciated and is dependent on the cell context to determine whether mERRa acts as a repressor or an activator.
